Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Operating Leases (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Operating Leases readings, the most recent being $16519.8 for Q4 2022.

  • On a quarterly basis, Operating Leases fell 71.42% to $16519.8 in Q4 2022 year-over-year; TTM through Dec 2022 was $16519.8, a 71.42% decrease, with the full-year FY2022 number at $16519.8, down 71.42% from a year prior.
  • Operating Leases hit $16519.8 in Q4 2022 for Cardiol Therapeutics, down from $27185.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $120094.7 in Q4 2020 to a low of $16519.8 in Q4 2022.
  • Median Operating Leases over the past 3 years was $52851.2 (2021), compared with a mean of $54486.5.
  • The widest YoY moves for Operating Leases: up 45.5% in 2022, down 71.42% in 2022.
  • Cardiol Therapeutics' Operating Leases stood at $120094.7 in 2020, then tumbled by 51.86% to $57811.2 in 2021, then tumbled by 71.42% to $16519.8 in 2022.
  • The last three reported values for Operating Leases were $16519.8 (Q4 2022), $27185.0 (Q3 2022), and $37800.5 (Q2 2022) per Business Quant data.